Market Value1,386,784,000
Total Holdings57
File Date2021-11-15
Original Filing (Click here)

All hedge funds or institutions that manage over $100M are required by the SEC to file quarterly reports on their holdings. These reports are called 13F reports. However, the filings are required the following quarter from the reporting period, which means that by the time the filing is made (and we see them), the information could be five months old.

For funds with long term positions that make few trades, the holdings might closely resemble their current holdings, even after several months. However, for funds that have high turnover, the holdings data we see might differ significantly from their current holdings. Institutions are required to report CALL and PUT options, and those positions are identified in the table. However, they are not required to report short positions.

Click the link icon to see the full transaction history.

Upgrade to unlock premium data and export to Excel .

Security Imputed
Share Price
Prev
Shares
Current
Shares
Change
(Percent)
Prev Value
(USD x1000)
Current Value
(USD x1000)
Change
(Percent)
KNSA / Kiniksa Pharmaceuticals, Ltd.
TALS / Talaris Therapeutics Inc
KZR / Kezar Life Sciences, Inc.
FMTX / Forma Therapeutics Holdings Inc
DAWN / Day One Biopharmaceuticals, Inc.
EPIX / ESSA Pharma Inc.
NKTX / Nkarta, Inc.
IOVA / Iovance Biotherapeutics, Inc.
BMEA / Biomea Fusion, Inc.
LABP / Landos Biopharma, Inc.
ATHA / Athira Pharma, Inc.
HARP / Harpoon Therapeutics, Inc.
ALPN / Alpine Immune Sciences, Inc.
DCPH / Deciphera Pharmaceuticals, Inc.
MREO / Mereo BioPharma Group plc - Depositary Receipt (Common Stock)
CGEM / Cullinan Therapeutics, Inc.
SYBX / Synlogic, Inc.
ALT / Altimmune, Inc.
OMGA / Omega Therapeutics, Inc.
PRDS / Pardes Biosciences Inc
ARYD / ARYA Sciences Acquisition Corp IV
TNGX / Tango Therapeutics, Inc.
TPTX / Turning Point Therapeutics Inc
GLUE / Monte Rosa Therapeutics, Inc.
CCCC / C4 Therapeutics, Inc.
ASLN / ASLAN Pharmaceuticals Limited - Depositary Receipt (Common Stock)
RACB / Research Alliance Corp II - Class A
HSAQ / Health Sciences Acquisitions Corp 2
PASG / Passage Bio, Inc.
GRPH / Graphite Bio, Inc.
PRLD / Prelude Therapeutics Incorporated
STTK / Shattuck Labs, Inc.
GHRS / GH Research PLC
BCEL / Atreca, Inc.
HLXA / Helix Acquisition Corp - Class A
ELDN / Eledon Pharmaceuticals, Inc.
CNTA / Centessa Pharmaceuticals plc - Depositary Receipt (Common Stock)
TIL / Instil Bio, Inc.
IPSC / Century Therapeutics, Inc.
KRTX / Karuna Therapeutics, Inc.
ARNA / Arena Pharmaceuticals Inc
PMVP / PMV Pharmaceuticals, Inc.
KNTE / Kinnate Biopharma Inc.
DICE / DICE Therapeutics Inc
JNCE / Jounce Therapeutics Inc
RAPT / RAPT Therapeutics, Inc. Call
SLGC / Standard BioTools Inc.
RAPT / RAPT Therapeutics, Inc.
IKNA / Ikena Oncology, Inc.
RAIN / Rain Enhancement Technologies Holdco, Inc.
ISEE / IVERIC bio Inc
VRDN / Viridian Therapeutics, Inc.
RPTX / Repare Therapeutics Inc.
ALGS / Aligos Therapeutics, Inc.
NUVB.WS / Panacea Acquisition Corp. - Equity Warrant
ALXO / ALX Oncology Holdings Inc.
VERV / Verve Therapeutics, Inc.
DSGN / Design Therapeutics, Inc.
KROS / Keros Therapeutics, Inc.
DYN / Dyne Therapeutics, Inc.
TYRA / Tyra Biosciences, Inc.
ACRS / Aclaris Therapeutics, Inc.
NUVL / Nuvalent, Inc.
CMPS / COMPASS Pathways plc - Depositary Receipt (Common Stock)
APLS / Apellis Pharmaceuticals, Inc.
OLMA / Olema Pharmaceuticals, Inc.
COGT / Cogent Biosciences, Inc.
JANX / Janux Therapeutics, Inc.
ATXS / Astria Therapeutics, Inc.
BCYC / Bicycle Therapeutics plc - Depositary Receipt (Common Stock)
EWTX / Edgewise Therapeutics, Inc.
IDYA / IDEAYA Biosciences, Inc.
CYTK / Cytokinetics, Incorporated
ANNX / Annexon, Inc.